using the cancer cell's own recycling machinery against it
In the long struggle between medicine and cancer's capacity for adaptation, researchers at Virginia Commonwealth University have found a way to turn the cancer cell's own survival instincts against it. By engineering a molecule that commandeers the cell's internal recycling system — autophagy — to destroy the very protein that multiple myeloma cells depend on to evade treatment, the team has opened a conceptually new front in targeted therapy. The discovery, published in Cell Death & Disease, suggests that rather than fighting a cancer cell's adaptations, we might one day redirect them toward the cell's own undoing.
- Multiple myeloma cells have long outwitted standard proteasome inhibitors by activating a backup cleanup pathway, making drug resistance a persistent and deadly problem for the roughly 36,000 Americans diagnosed each year.
- VCU researchers engineered an AUTAC molecule that hijacks that very backup system — autophagy — forcing cancer cells to dismantle MCL1, the survival protein they rely on most.
- When combined with existing proteasome inhibitors in preclinical models, the dual approach cut myeloma cell viability in half within just 48 hours, while showing limited toxicity to heart tissue.
- The strategy marks a philosophical shift in cancer treatment: instead of blocking what a protein does, it eliminates the protein from the cell entirely.
- The team is now refining the molecule's potency through medicinal chemistry, with ambitions that stretch beyond myeloma to breast cancer, melanoma, and lung cancer — all of which share MCL1 as a survival dependency.
Researchers at VCU Massey Comprehensive Cancer Center have engineered a molecule that turns multiple myeloma's own survival strategy against it. The work, published in Cell Death & Disease, targets MCL1 — a protein cancer cells use to stay alive — by forcing the cell's internal recycling system, autophagy, to destroy it.
Multiple myeloma, a bone marrow cancer affecting around 36,000 Americans each year, has long been treated with proteasome inhibitors, drugs that overwhelm cancer cells by blocking their main protein-disposal pathway. But myeloma cells adapt: they activate autophagy as a workaround, clearing the toxic buildup and surviving. Rather than trying to block this escape route, the VCU team decided to weaponize it.
Their molecule — an AUTAC, or autophagy-targeting chimera — redirects the autophagy system to degrade MCL1 specifically. "We're using the autophagy response and degrading this critical protein and killing the cancer cells," said senior author Senthil K. Radhakrishnan. In preclinical testing, combining the AUTAC with a proteasome inhibitor reduced myeloma cell viability by 50 percent within 48 hours. Crucially, the molecule showed limited toxicity to heart tissue, a significant safety concern for any drug targeting MCL1.
The approach represents a broader shift in oncology thinking: rather than silencing a protein's function, targeted degraders remove the protein from the cell entirely. The team views this study as proof of concept and is now working to make the molecule more potent. Because MCL1 also drives survival in breast cancer, melanoma, and lung cancer, the implications of this research may reach well beyond myeloma.
Researchers at VCU Massey Comprehensive Cancer Center have found a way to turn a cancer cell's own cleanup machinery against itself. The discovery, published in Cell Death & Disease, centers on a new molecule that hijacks autophagy—the cellular recycling process—to destroy a protein that multiple myeloma cells need to survive.
Multiple myeloma, a cancer of white blood cells in bone marrow, affects roughly 36,000 Americans annually and strikes most often in people over 65. For years, doctors have relied on proteasome inhibitors, drugs that block the cell's main protein-disposal system. When the proteasome shuts down, unwanted proteins pile up inside cancer cells and become toxic. But myeloma cells are cunning: they've learned to activate autophagy as a workaround, using the cell's secondary cleanup pathway to clear away the toxic buildup and survive the treatment. This adaptation is why drug resistance remains a stubborn problem in the disease.
Instead of trying to block autophagy—the conventional thinking—the VCU team took a different path. They engineered a molecule called an AUTAC, short for autophagy-targeting chimera, that forces cancer cells to use their autophagy system to destroy a specific survival protein called MCL1. "We're using the autophagy response and degrading this critical protein and killing the cancer cells," explained Senthil K. Radhakrishnan, the study's senior author and a pathology professor at VCU. "MCL1 is usually broken down through the proteasome, but we're forcing MCL1 to be degraded through autophagy."
When the research team tested their AUTAC molecule alongside a proteasome inhibitor in preclinical myeloma models, the results were striking. Within 48 hours, the combination reduced cancer cell viability by 50 percent. Ahmed Elshazly, the study's lead author, confirmed that the complete molecule successfully triggered cancer cell death. Equally important, when the team examined the AUTAC's effects on heart tissue—a major safety concern for drugs targeting MCL1—they found limited toxicity while the molecule retained its cancer-killing power. The researchers also demonstrated that the approach worked against non-small cell lung cancer, suggesting broader potential.
Targeted protein degradation represents a new frontier in cancer treatment. Rather than merely blocking a protein's function, these drugs aim to eliminate the protein entirely from the cell. This approach differs fundamentally from most existing therapies, which work by shutting down what proteins do rather than removing them altogether. The VCU findings suggest that by combining this degradation strategy with existing drugs, researchers can overcome one of multiple myeloma's most frustrating characteristics: the ability to adapt and survive.
Radhakrishnan and his team are now working to strengthen their molecule through medicinal chemistry, treating this study as proof of concept rather than a finished product. They plan additional preclinical testing before moving forward. The implications extend beyond myeloma. MCL1 is a survival factor in breast cancer, melanoma, and lung cancer as well, meaning this approach could eventually help patients with several different malignancies. For now, the focus remains on refinement—making the molecule more potent and preparing it for the next phase of research.
Citações Notáveis
Our findings point to a new way of using the cancer cell's own recycling machinery against it, with the goal of making existing treatments more effective.— Senthil K. Radhakrishnan, senior author and pathology professor at VCU
After 48 hours, we saw a 50% reduction in multiple myeloma cell viability in preclinical models. We confirmed that our drug, as a complete molecule, is able to induce cancer cell death.— Ahmed M. Elshazly, study lead author and Ph.D. candidate at VCU
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that you're using autophagy instead of blocking it?
Because myeloma cells have already learned to use autophagy as an escape route when proteasome inhibitors block their main protein disposal system. If you just block autophagy too, you're fighting the cell on two fronts but the cell adapts. We're instead weaponizing autophagy against the cell—forcing it to destroy the exact protein it needs to live.
So you're hijacking the cell's own survival mechanism?
Exactly. The AUTAC molecule acts like a Trojan horse. It tells the autophagy system to specifically target and destroy MCL1, the protein keeping myeloma cells alive. The cell's own recycling machinery becomes the instrument of its own death.
Why is the 50 percent reduction in 48 hours significant?
It shows the combination works fast and decisively in preclinical models. But more importantly, it works *without* the cardiac toxicity that's plagued other MCL1-targeting drugs. That's the safety breakthrough—you get the killing power without damaging the heart.
What happens next in the lab?
We optimize the molecule itself. This is proof the concept works, but we can make it more potent through chemistry. Then we test those improved versions in more preclinical studies before anything approaches human trials.
Could this work for other cancers?
That's the real possibility. MCL1 is a survival factor in breast, lung, and melanoma cells too. If the approach works here, the same strategy could apply across multiple tumor types.